COMBourse - Analyse graphique de l'actualite, des actions et des societes
Accueil > Sociétés > Pharmacie > SANOFI AVENTIS
SOCIETE : 
SECTEUR : Santé et Pharmaceutiques > Pharmacie
NEWS :  231 sur 1 an | 15 sur 1 mois | 3 sur 72h | 2 sur 12h | ISIN : FR0000120578
TVIC 1mois :  +6% En savoir plus sur le Taux de variation d'information
Communication Officielle
Mardi 15 juin 2021, 16h05  (il y a 34 mois)

ALPHA MOS : Ben Delhey joins as Supervisory Board Member of BOYDSense, the MedTech subsidiary of Alpha MOS

PRESS RELEASE
Toulouse, 15.06.2021


Ben Delhey joins as Supervisory Board Member of BOYDSense, the MedTech subsidiary of Alpha MOS


BOYDSense SAS, a subsidiary of ALPHA MOS (EuroNext: ALM), developed a miniaturized respiratory analysis platform to monitor chronic diseases, with a first application in diabetes monitoring. Today, BOYDSense is announcing the arrival mid-June of Ben Delhey as Supervisory Board independent member.


Ben Delhey has more than 15 years of senior management experience in the Healthcare industry. He has been working within leading diabetes Medtech and Pharma companies such as LifeScan, Ascencia and Sanofi.


Ben Delhey is a specialist in the launch of pharmaceutical devices. During his career in Sales and Marketing, he has launched more than 10 diabetes devices and software as medical devices which are distributed in more than 25 countries in the world. These major devices are world famous brands such as OneTouch® Vita®, MyStar® from Sanofi and Mhealth Software, My Dose Coach®.


“I am very excited to join the BOYDSense team. We are starting a new era in terms of technologies applied to diabetes. The last few years have been really interesting with the release of brand-new innovations. The BOYDSense device will drastically improve the way patients with diabetes will measure their blood glucose level. This is great news for patients with diabetes, because this innovation will greatly facilitate their daily life and allow them to monitor their glucose levels in a more gentle way.” commented Ben Delhey.


Anton Kittelberger, Chairman of the Supervisory Board of BOYDSense, added : “Ben is the perfect addition to our team. He will bring us his huge experience in terms of diabetes, acces to the market and launching of medical devices. We are very confident because Ben has already done all these missions for Sanofi, BAYER or Johnson & Johnson. We are really looking forward to working together on our next succes.”


About Alpha MOS
Alpha MOS is the world's leading manufacturer of electronic nose, tongue and eye for industrial use.
Founded in 1993, ALPHA MOS is specialized in Volatile Organic Compounds (VOCs) analysis and the digitization of smell, taste and vision. Located in France, in China and in the United States, the company manages over 1000 installs worldwide.
For more information: https://www.alpha-mos.com/

Media contact
Alpha MOS : 33 5 62 47 53 80
(Dentsu Consulting) Gildas de la Monneraye : gildas.delamonneraye@dentsuconsulting.fr / 33 6 58 18 78 25

------------------------
Cette publication dispose du service "Actusnews SECURITY MASTER".
- SECURITY MASTER Key : x2meYZucY5rGnWufZJuWb5aZbphqw2TIbpbGnJZwlJbHnXBgmm2SaprIZm9qnGVs
- Pour contrôler cette clé : https://www.security-master-key.com.
------------------------
Communiqué intégral et original au format PDF :
Télécharger le PDF
© Copyright Actusnews Wire
Recevez gratuitement par email les prochains communiqués de la société en vous inscrivant sur www.actusnews.com

Mardi 15 juin 2021, 16h05 - LIRE LA SUITE
Les dernières News : SANOFI AVENTIS
Partager : 






Flux Rss SANOFI AVENTIS :



Départs précipités, perte nette, projet de scission « mal ficelé »… La vérité sur le naufrage d’Euroapi Challenges.fr
02 avril
Sanofi sort le chéquier pour éteindre les plaintes américaines liées au Zantac Lesechos.fr
04 avril
Innate Pharma annonce la progression de l’essai clinique évaluant le NK Cell Engager SAR443579 / IPH6101 développé par Sanofi vers la Phase 2 dans divers cancers du sang Businesswire.fr
15 avril